Form 4 for KPTI Karyopharm Therapeutics Inc.
Accepted 2024-11-06 00:00:00 ET · period of report 2024-11-05 · accession 0000950170-24-122274 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-11-06 | 2024-11-05 | KPTI | Paulson Richard A. | Pres, CEO, Dir | S - Sale | $0.91 | -3,675 | 1.13M | -0.3% | -$3,344 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-11-05 | S | D | 3,675 | $0.91 | 1,131,932 | D | — | — | (F2) Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $0.9101 to $0.9350, inclusive. The reporting person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. |